1026540-67-9

Upstream product

• 56547-82-1 1-cyclohexyl-3-methyl-1H-pyrazol-5-amine 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 108-94-1 cyclohexanone 
• 24214-73-1 cyclohexylhydrazine hydrochloride 
• 60295-21-8 N'-cyclohexyl-hydrazine carboxylic acid tert-butyl ester 
• 60295-11-6 tert-butyl 2-cyclohexylidenehydrazine-1-carboxylate 
• 6498-34-6 cyclohexylhydrazine 

Downstream Products

• 851520-97-3 4-chloro-1-cyclohexyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid amide 
• 1027978-60-4 4-chloro-1-cyclohexyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 1027293-98-6 4-chloro-1-cyclohexyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl chloride 
• 1027160-55-9 4-chloro-1-cyclohexyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION

Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.